entresto
novartis europharm limited - sacubitril, valsartan - südamepuudulikkus - angiotensiin ii antagonistidega, muud kombinatsioonid, toimivad ained renin-angiotensiini süsteemi - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
neparvis
novartis europharm limited - sacubitril, valsartan - südamepuudulikkus - reniini-angiotensiini süsteemi toimivad ained - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.
doxyprim 40% suukaudse lahuse pulber
lavet pharmaceuticals ltd. - doksütsükliin - suukaudse lahuse pulber - 400mg 1g 10000g 1tk; 400mg 1g 1000g 1tk; 400mg 1g 5000g 1tk
phenhydan injektionslösung süstelahus
desitin arzneimittel gmbh - fenütoiin - süstelahus - 50mg 1ml 5ml 5tk
adrenaline demo süste-/infusioonilahus
demo s.a. - epinefriin (adrenaliin) - süste-/infusioonilahus - 1mg 1ml 1ml 50tk
eprinex multi kriipsulahus
boehringer ingelheim animal health france - eprinomektiin - kriipsulahus - 5mg 1ml 2500ml 1tk; 5mg 1ml 250ml 1tk; 5mg 1ml 5000ml 1tk
adrenaline demo süste-/infusioonilahus
ideal trade links uab - epinefriin (adrenaliin) - süste-/infusioonilahus - 1mg 1ml 1ml 25tk; 1mg 1ml 1ml 50tk
malaseb šampoon
dechra veterinary products a/s - mikonasool+kloorheksidiin - šampoon - 20mg+20mg 1ml 250ml 1tk
procoralan
les laboratoires servier - ivabradiinvesinikkloriid - angina pectoris; heart failure - südame teraapia - sümptomaatiline ravi kroonilise stabiilse stenokardia ivabradiin on näidustatud täiskasvanutel pärgarteri haigus normaalse siinusrütmiga südame löögisagedus minutis on ≥ 70 kroonilise stabiilse stenokardia sümptomaatiliseks raviks. ivabradine is indicated :in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. ravi kroonilise südamepuudulikkuse ivabradiin on näidustatud kroonilise südamepuudulikkuse nyha ii – iv klassi, patsientidel siinusrütm ja kelle pulsisagedus on üle 75 löögi minutis, sealhulgas beetablokaatoriga ravi koos või kuna beetablokaatoriga ravi on vastunäidustatud või mittetalutav.
vidaza
bristol-myers squibb pharma eeig - asatsitidiin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastilised ained - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.